Kornimate/medical-research-clean huggingface dataset:
a pilot study to determine nutrition status in glioblastoma multiforme patients

Conditions: Brain Cancer

Summary: the study is designed to evaluate how the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis can predict the progression and outcomes of disease.

the purpose of this study is to monitor the nutritional status of (glioblastoma multiforme)gbm patients for one year. we will look at the relationships between phase angle determined by bioelectrical impedance analysis (bia), nutrition assessment by subjective global assessment and serum albumin, the type of microbes present in the gut, the participant's dna information, and tumor progression. we will also compare estimated caloric needs determined by bia and harris benedict equation to resting energy expenditure from indirect calorimetry of the people with gbm and the people without.

Eligibility criteria:
inclusion criteria: * subjects must be at least 19 years of age. * subjects must have a histologically confirmed supratentorial grade iv astrocytoma (glioblastoma multiforme). * women of childbearing potential must have a negative pregnancy test. exclusion criteria: * subjects with implanted pacemakers or defibrillators. * subjects who are pregnant. * subjects with edema. * subjects with an amputated extremity.
portal vein embolization in treating patients with liver metastases from primary colorectal cancer

Conditions: Colorectal Cancer; Metastatic Cancer

Summary: rationale: embolization blocks blood flow to part of an organ and/or tumor. blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. purpose: phase ii trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.

objectives: * determine whether portal vein embolization results in significant hypertrophy of the remaining liver and potentially decreases the risk of liver failure after hepatic resection in patients with liver metastases from primary colorectal cancer. * determine the biologic effects of this therapy on liver metastases and normal liver parenchyma in these patients. outline: patients undergo portal vein embolization with 200-300 micron polyvinyl chloride particles suspended in iohexol 300. approximately 3-6 weeks after embolization, patients undergo an exploratory laparotomy followed by hepatic surgical resection. patients are followed for at least 6 months. projected accrual: a total of 25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed primary colorectal adenocarcinoma with metastases to the liver being considered for hepatic resection * requirement for removal of at least 60% of functional liver parenchyma based on ct scan * no extrahepatic disease by laparoscopy patient characteristics: age: * over 18 performance status: * ecog 0-2 life expectancy: * not specified hematopoietic: * wbc at least 2,000/mm3 * platelet count at least 100,000/mm3 hepatic: * bilirubin no greater than 1.8 mg/dl * ast and alt no greater than 80 iu/l renal: * creatinine no greater than 1.8 mg/dl cardiovascular: * no new york heart association class iii or iv heart disease other: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least 1 month since prior systemic chemotherapy endocrine therapy: * not specified radiotherapy: * not specified surgery: * see disease characteristics other: * at least 2 months since prior investigational treatment

Keywords: liver metastases adenocarcinoma of the colon recurrent colon cancer stage iv colon cancer adenocarcinoma of the rectum recurrent rectal cancer stage iv rectal cancer
a study to assess the biological potency of peanut allergen extract in adolescent and adult peanut allergic subjects

Conditions: Peanut Allergy

Summary: the study aims to assess the biological potency of the in-house reference preparation (ihrp) of peanut allergens extract by a quantitative skin prick test (spt) method in peanut-allergic subjects.


Eligibility criteria:
main inclusion criteria: * male or female subjects aged between 12-50 years * physician-diagnosed peanut allergy * subject currently following a strict peanut-free diet * documented history of positive test to peanut-specific ige (immunocap system) \>0.7 ku/l * positive peanut spt with a largest wheal diameter ≥ 8 mm main exclusion criteria: * uncontrolled asthma * peanut allergen immunotherapy whatever the route, either ongoing or previously started and having lasted more than one month (\>30 days) * topical use of steroids within the past 14 days prior to the screening spt * inability to discontinue short-acting antihistamines * atopic dermatitis, eczema or urticaria on the areas to be tested

Keywords: epit epicutaneous immunotherapy viaskin
plasma proteomics in patients with postoperative delirium

Conditions: Postoperative Delirium

Summary: patients undergoing cardiac surgery were recruited. baseline characteristics of all subjects were collected. the 3-minute delirium diagnostic scale (3d-cam) was used to screen the pod group and non-pod group from the recruited subjects during the first 7 days after surgery. peripheral blood samples were collected 1 day before surgery and 2 day after surgery. . plasma was isolated from peripheral blood for subsequent proteomic analysis.

patients undergoing noncardiac surgery were recruited. baseline characteristics of all subjects were collected. the 3-minute delirium diagnostic scale (3d-cam) was used to screen the pod group and non-pod group from the recruited subjects during the first 7 days after surgery. peripheral blood samples were collected 1 day before surgery and 2 day after surgery. plasma was isolated from peripheral blood for subsequent proteomic analysis. to study the characteristics of proteins on a large scale, including protein expression levels, post-translational modifications, protein-protein interactions, etc., so as to obtain a comprehensive understanding of disease occurrence, cell metabolism and other processes at the protein level. assessment of imbalanced protein expression in peripheral blood using protein profiling may allow us to better understand the pathological changes occurring at the molecular level of pod. early detection of patients at high risk of pod can optimize perioperative management and promote rapid postoperative recovery.

Eligibility criteria:
inclusion criteria: * age ≥65 years old, regardless of gender. * the patient had clear consciousness and no cognitive impairment, and could cooperate with the investigation and follow-up. * the asa classification is i-ⅲ. exclusion criteria: * severe neurological or psychiatric disorders. * drug and alcohol abuse. * patients with cognitive impairment caused by various reasons such as neuropsychiatric symptoms. * exclusion criteria included incomplete medical records and failure to complete the postoperative follow-up.
effects of shi style cervical mobilization versus snags in patients with cervicogenic headache

Conditions: Cervicogenic Headache

Summary: cervicogenic headache (cgh) manifests as unilateral neck pain referred from the neck's soft tissues or bony structures. the aim of this study will be to compare the effectiveness of shi style cervical mobilization versus sustained natural apophyseal glides on pain, strength and functional disability in patients with cervicogenic headache.

a randomized clinical trial will be conducted at jinnah hospital lahore through consecutive sampling technique on 40 patients which will be allocated using simple random sampling through sealed opaque enveloped into group a and group b. group a will be treated with shi style mobilizations with 6 sesions over 4 weeks for 20minutes. group b will be treated with sustained natural apophyseal glides with number of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10seconds. outcome measures will be conducted through nprs for pain , deep neck flexors strength by pressure biofeedback, dizziness handicap inventory for pain and change in dizziness, ndi for functional impairments and sf 36 for quality of life.data will be analyzed through spss software version 25 .

Eligibility criteria:
inclusion criteria: * age:18 to 65 years. * both male and females. * unilateral dominant headache. * positive international headache society diagnostic criteria (ihs) for cervicogenic headache. * decrease strength deep neck flexors by pressure biofeedback. * tenderness of the upper 3 cervical spine joints. exclusion criteria: * • patients who received any treatment for cgh within the previous 3 months that would interfere with this study. * pregnant females. * inflammatory conditions in which manual therapy is contraindicated(29). * cancer or brain diseases. * recent fracture or injuries. * congenital conditions of the cervical spine.

Keywords: muscle strength manual therapy unilateral headaches
uhn inpatient hepatitis c & b screening

Conditions: Hepatitis C; Hepatitis B

Summary: currently, there is a lack of literature on programs evaluating rapid screening methods to traditional venipuncture methods for sample collection during screening for viral hepatitis. due to the relatively low diagnosis and linkage to care rate, screening programs that provide same day results for viral hepatitis infection may improve both diagnosis and enable providers to engage patients shortly after diagnosis. this stands in contrast to the multi-visit, weeks long process that normally accompanies serum testing for hepatitis c virus (hcv) and hepatitis b virus (hbv). a few american studies have examined the implementation of hcv inpatient screening programs; however, they are focused specifically on high-risk patient populations, the barriers to accessing care experienced by study participants are not relevant to the canadian healthcare system context, and do not use rapid testing. furthermore, there are few, if any, data on hbv inpatient screening programs and the diagnosis rate remains low. this project will provide key data on a rapid inpatient screening and linkage to care strategy as well as the prevalence of these viruses across different age bands within the population. finally, the study will help determine whether rapid inpatient screening is a feasible and acceptable approach for screening and linkage to care.


Eligibility criteria:
inclusion criteria: * adults aged 18 years or older at time of consent * patients admitted to gimius at tgh or twh exclusion criteria: * patients whose end of life is expected to be less than 6 months * patients who are unable or decline to provide informed consent * patients with confirmed, active covid-19 infections * patients with immediate life-threatening conditions where screening for chronic hcv and hbv infection may delay urgent care

Keywords: hepatitis c hepatitis b screening inpatient hospital
staccato: a trial of cd4 guided treatment interruption, compared to continuous treatment, for hiv infection

Conditions: HIV Infection; AIDS

Summary: treatment of hiv repairs the immune system, but continuous treatment is expensive and causes side effects. would it not be better to treat intermittently, e.g. stop treatment when the immune system has recovered, and start again only when damage reappears? that is the question which staccato proposes to answer. approximately 500 patients were recruited for this trial from 2002 to 2004. one third were treated continuously; in two thirds, the treatment was interrupted whenever the cd4 count, a measure of immune recovery, exceeded 350. at the end of 2005, the two treatment groups will be compared in order to see which fared better regarding amount of drugs used, side effects, cd4 counts, and development of resistance to treatment.

continuous treatment has been very successful in diminishing the diseases and deaths caused by hiv. however, continuous treatment is expensive. intermittent treatment will always cost less than continuous treatment, and therefore has the potential to facilitate access to highly active antiretroviral therapy (haart) in developing countries. haart also causes many undesirable effects. intermittent treatment decreases exposure to drugs and is therefore expected to decrease side effects. staccato is a randomised trial of intermittent versus continuous anti-retroviral treatment. at least 600 patients on haart, with viremia below 50 copies/ml and cd4 count above 350 cells/ml were randomised to one of two arms, in 1:2 proportions: * arm 1: continuation (control) arm: drugs are continued or changed according to current guidelines and good clinical practice. * arm 2: cd4-guided arm: drugs discontinued and reintroduced according to cd4 counts, with haart being administered only if cd4 count is \< 350 cells/ml. randomized treatment will continue during an average of approximately 2 years, and will be followed by a period of 12 to 24 weeks' continuous treatment, for patients in both arms. endpoints: the amount of drugs used, side effects, viremia and cd4 counts, number of clinical events, at the end of the randomized treatment period, and again 12 to 24 weeks later. a subproject will study the effect of treatment interruption on resistance development, mutations in proviral dna and proviral dna levels.

Eligibility criteria:
inclusion criteria: * cd4 lymphocyte count above 350/microliter and viral hiv1-rna below 50 copies/ml on antiretroviral treatment. exclusion criteria: * virologic failure of treatment. failure of treatment defined as a treatment switch motivated by high viral loads on treatment.

Keywords: scheduled treatment interruptions sti
a study of kl130008 in adults with severe alopecia areata

Conditions: Alopecia Areata

Summary: the purpose of this study is to assess kl130008 is safe and effective in adults with severe alopecia areata

this is a multi-center phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (at) and alopecia universalis (au).

Eligibility criteria:
inclusion criteria: 1. male or female subjects with the age of ≥18 and ≤ 65 years old at the time of informed consent. 2. able to understand the procedures and methods of this study, and will to provide a signed and dated informed consent form. 3. diagnosed alopecia areata(aa) without other reasons caused alopecia. 4. have severe aa, as determined by all of the following:current aa episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, including alopecia totalis (at) and alopecia universalis (au);no spontaneous improvement over the past 6 months;current episode of severe aa of less than 8 years. 5. all women of childbearing potential and all men must be willing to use at least one highly effective method of contraception from the signing of informed consent, throughout the duration of the study, and for 3 months after the last dose of investigational drugs. exclusion criteria: 1. known history of anaphylaxis to any of the ingredients and/or other similar products. 2. participated in a clinical trial of any drug or medical device and has used an investigational product (including placebo and control group) or treatment within 1 month or 5 half-lives before randomization. 3. previously treated with jak inhibitors. 4. corticosteroids, finasteride, minoxidil,topical immunotherapy treated within 8 weeks before randomization. 5. diphenylcyclopropenone (dpcp), hmgcoa reductase inhibitor, chinese herbal medicine treated within 4 weeks before randomization. 6. with other diseases: acute "diffuse" type of aa, lymphoproliferative disease, tumor, severe chronic gastrointestinal disease, thyroid disorders, serious cardiovascular disease. 7. subjects with evidence of clinical laboratory abnormalities at screening that, in the opinion of the investigator, may affect the safety of subjects or the interpretation of study results: hemoglobin level \ 2 × uln, total bilirubin(tbil)\>1.5 × uln. qtcf\> 450ms. subjects with egfr ≤ 60 ml/min based on cockcroft-gault calculation. 8. the subject had or currently has a severe infection, and had a severe infection judged by the investigator within 1 month before randomization: hbv, tp-ab, hiv, hcv, tb positive. 9. subjects who are unsuitable to the trial, as identified by the investigator.

Keywords: alopecia areata hypotrichosis hair diseases
comparison of tace versus tace/taci combination in advanced hepatocellular carcinoma with portal vein invasion

Conditions: Hepatocellular Carcinoma

Summary: the aim of this study is to compare the efficacy of transarterial chemoembolization with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion with cisplatin combination in advanced hepatocellular carcinoma with portal vein invasion.

potentially curative treatments for hepatocellular carcinoma (hcc) include surgical resection, liver transplantation, and local ablative therapy. however, hcc patients are diagnosed at advanced stages in korea. especially, hccs with portal vein invasion are unresectable and they are not suitable for other curative therapies. for these patients, the optimal treatment remains largely controversial. as a palliative treatment, the benefit of transarterial chemoembolization (tace) had been shown in patients with unresectable hcc and without portal vein invasion by several trials. in patients with main portal vein invasion, tace is theoretically contraindicated because of the potential risk of hepatic failure resulting from ischemia after tace. however, recent studies have revealed that tace could safely be performed in these patients. the aim of this study is to compare the efficacy of transarterial chemoembolization (tace) with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion (taci) with cisplatin combination in advanced hepatocellular carcinoma with portal vein invasion.

Eligibility criteria:
inclusion criteria: * patients with clinical or histological diagnosis of hcc based on the guidelines of the ajcc * patients with advanced hcc with invasion of major branch(es) of portal vein in the arterial phase of dynamic ct or mri * patients who have received previous local therapy treatments (rfa, pei, cryoablation, surgery, resection) are eligible * age : 18 years to 80 years * ecog performance status of 0 to 2 * child-pugh class a (child-pugh score 5-6) * adequate bone marrow, liver function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: * wbc count \> 2,000/mm3 * absolute neutrophil count \> 1,000/mm3 * hb ≧ 8.0 g/dl * platelet count ≧ 50,000 /mm3 * bilirubin ≦ 3 mg/dl * adequate clotting function: inr \< 2.3 or \< 6sec exclusion criteria: * child-pugh score ≧ 7 * ecog performance status ≧ 3 * patients with chronic kidney disease or serum creatinine ≥ 1.2 mg/dl * history of organ allograft * patients with uncontrolled co-morbidity which needs treatment * patients who have received prior systemic chemotherapy * patients with extrahepatic metastasis

Keywords: hepatocellular carcinoma portal vein invasion transarterial chemoembolization transarterial chemoinfusion
trial of alternating current stimulation in optic neuropathy

Conditions: Optic Nerve Diseases; Optic Nerve Injuries; Optic Neuropathies

Summary: non-invasive brain stimulation can increase cortical excitability in the visual system, but it is not known if this is of clinical value. the investigators now assessed if repetitive, transcranial alternating current stimulation (rtacs) can improve visual field size in patients with optic nerve damage. the investigators hypothesized that rtacs would improve visual functions within the defective visual field sectors of the visual field (primary outcome measure).

in a prospective, double-blind, randomized, placebo-controlled clinical trial 22 patients with optic nerve damage were randomly assigned to a rtacs- (n=12) or placebo-group (n=10). visual field measures, visual acuity and eeg-recordings were collected before and after a daily 20-40min treatment for 10-days and at a 2-months-follow-up. primary outcome measure was detection accuracy (da) in defective visual field sectors of computer-based high resolution perimetry (hrp). secondary outcome parameters included da in static and kinetic perimetry, reaction time (rt) in hrp, visual acuity (va), contrast vision, and eeg power spectra.

Eligibility criteria:
inclusion criteria * patients with optic nerve lesion * stable visual field defect with residual vision * lesion age at least 6 months exclusion criteria * heart pacemakers and any metal artefacts in head and truncus * epileptic seizure within the last 3 years * photosensitive epilepsy as determined by eeg * mental diseases (schizophrenia etc.) * unstable diabetes, diabetes causing diabetic retinopathy * macular degeneration, maculopathy with decimal visual acuity below 0.4 * high blood pressure * instable or high level of intraocular pressure (i.e. \>27 mmhg) * presence of an un-operated tumor anywhere in the body * total blindness * primary or secondary glaucoma * pathological nystagmus

Keywords: optic neuropathy alternating current stimulation vision recovery restoration plasticity
randomized trial of docetaxel and gemcitabine versus gemcitabine in elderly patients with nsclc

Conditions: Non-small-cell Lung Cancer

Summary: this trial will compare the efficacy of the docetaxel and gemcitabine combination versus monotherapy with gemcitabine as first-line treatment in elderly patients with advanced nsclc

docetaxel and gemcitabine are well known active agents in the treatment of nsclc. the standard treatment of elderly patients with advanced nsclc is monotherapy with a third generation agent. however, there are only few randomized trials evaluating a two drug combination specifically addressed to elderly patients. the role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation

Eligibility criteria:
inclusion criteria: * histologically- or cytologically- confirmed non-small-cell lung cancer * stage iiib/iv * no prior chemotherapy * presence of two-dimensional measurable disease. the measurable disease should not have been irradiated. * absence or irradiated and stable central nervous system metastatic disease * life expectancy of more than 3 months * age ≥ 70 years. * performance status (who) \< 3 * patients "non-frail" according to comprehensive geriatric assessment * adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9gr/mm\^3). * adequate liver (bilirubin \< 1.5 times upper limit of normal and sgot/sgpt \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl). * adequate cardiac function (lvef \> 50%). * informed consent. exclusion criteria: * psychiatric illness or social situation that would preclude study compliance. * other concurrent uncontrolled illness. * other invasive malignancy within the past 5 years except nonmelanoma skin cancer. * no presence of a reliable care giver * other concurrent investigational agents.

Keywords: cancer nsclc elderly chemotherapy docetaxel gemcitabine